Retirement Systems of Alabama Has $24.54 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Retirement Systems of Alabama lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 384,625 shares of the biopharmaceutical company's stock after selling 5,457 shares during the quarter. Retirement Systems of Alabama owned 0.31% of Halozyme Therapeutics worth $24,543,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in HALO. Norges Bank acquired a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $60,054,000. Capital World Investors acquired a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $35,773,000. Arrowstreet Capital Limited Partnership increased its stake in Halozyme Therapeutics by 141.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock valued at $47,470,000 after buying an additional 581,475 shares during the period. D. E. Shaw & Co. Inc. increased its stake in Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after buying an additional 524,802 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $21,838,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

HALO has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price for the company. in a research report on Tuesday, May 13th. Morgan Stanley downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $73.00 to $62.00 in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $61.90.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 503 shares of the company's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now directly owns 33,108 shares in the company, valued at $2,120,567.40. This represents a 1.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $52.81 on Friday. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13. The company has a fifty day simple moving average of $56.73 and a 200 day simple moving average of $56.24. The company has a market cap of $6.51 billion, a P/E ratio of 14.05, a P/E/G ratio of 0.35 and a beta of 1.19. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. The business had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. Halozyme Therapeutics's quarterly revenue was up 35.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.79 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.